TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Caplin Point Lab Ltd.
CAPLIPOINT

Caplin Point Lab Ltd. Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 74/100 · Good See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹2,835.1

Change

-32.3 (-1.13%)

Open

₹2,867.0

Prev. Close

₹2,867.4

Day High

₹2,909.6

Day Low

₹2,785.0

Volume Analysis

Traded

181,149

Delivered

37,049

Delivery %

20.45%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (3)

  • •Trading within 3% of its 52-week high (₹2877.0)
  • •Strong return on equity (20.9%)
  • •Strong operating margin (35.0%)

Weaknesses (0)

No signal for this stock

Opportunities (2)

  • •Strong 3-year EPS growth (19.4%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹3,026.06 ₹2,967.83 ₹2,901.46 ₹2,843.23 ₹2,776.86 ₹2,718.63 ₹2,652.26
Fibonacci ₹2,967.83 ₹2,920.23 ₹2,890.83 ₹2,843.23 ₹2,795.63 ₹2,766.23 ₹2,718.63
Camarilla ₹2,869.37 ₹2,857.94 ₹2,846.52 ₹2,843.23 ₹2,823.68 ₹2,812.26 ₹2,800.84

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+57.6%

1 Week

+2.85%

1 Month

+12.63%

3 Months

+7.96%

6 Months

+80.57%

1 Year

+39.19%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹245.57

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

2.13%

Net margin 29.65% × asset turnover 0.06x × equity multiplier 1.2x

Company Overview

Sector

Healthcare

Market Cap

₹21,173 Cr

P/E (TTM)

31.9

ROE

20.9%

Book Value

₹443.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 23 Sep 2026. Not investment advice.

TopFund Analysis

Caplin Point Lab Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 74/100. The strongest factor is Financial Strength (100/100), while Valuation (28/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week high (₹2877.0); strong return on equity (20.9%). Strong 3-year EPS growth (19.4%).

TopFund Score — Fundamentals Quality

74/100 — Good

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

100

Growth

86

Valuation

28

Cash Flow

56

Corporate Governance

71

Momentum

93

Institutional Ownership

56

Business Quality

96

Risk & Volatility

70

Liquidity

50

From Screener.in

  • +Company is almost debt free.
  • +Company has delivered good profit growth of 21.4% CAGR over last 5 years
  • +Company's median sales growth is 19.9% of last 10 years

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Announcement under Regulation 30 (LODR)-Newspaper Publication 04 Sep

Newspaper Publication for Notice of 35th AGM and E-Voting Information

Letter To Shareholders 04 Sep

Caplin Point sent AGM notice and FY26 annual report web link; AGM on September 25, 2026.

Business Responsibility and Sustainability Reporting (BRSR) 03 Sep

Caplin Point filed BRSR for FY 2025-26, outlining ESG targets, compliance, workforce and operations.

Notice Of The 35Th Annual General Meeting 3 Sep 03 Sep
Reg. 34 (1) Annual Report. 3 Sep 03 Sep

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 395 410 436 453 459 483 493 502 510 534 543 600 610
Expenses + 269 273 293 308 307 318 331 334 332 345 353 396 397
Operating Profit 127 137 142 145 152 165 162 168 178 189 190 204 213
OPM % 32.0% 34.0% 33.0% 32.0% 33.0% 34.0% 33.0% 33.0% 35.0% 35.0% 35.0% 34.0% 35.0%
Other Income + 12 21 17 17 19 21 31 26 23 30 34 28 34
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 11 12 14 16 16 17 16 17 16 18 19 19 22
Profit before tax 127 146 145 146 154 168 177 177 184 201 204 213 225
Tax % 18.0% 20.0% 18.0% 17.0% 19.0% 22.0% 21.0% 18.0% 18.0% 20.0% 19.0% 19.0% 20.0%
Net Profit + 104 116 120 121 125 131 140 145 151 160 166 173 179
EPS in Rs 14 15 15 16 16 17 18 19 20 20 22 22 23
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 252 239 402 540 649 863 1,061 1,269 1,467 1,694 1,937 2,187 2,287
Expenses + 192 175 276 345 417 603 732 874 1,025 1,142 1,287 1,422 1,491
Operating Profit 60 64 125 195 232 260 329 395 442 552 651 765 797
OPM % 24.0% 27.0% 31.0% 36.0% 36.0% 30.0% 31.0% 31.0% 30.0% 33.0% 34.0% 35.0% 35.0%
Other Income + 3 4 10 13 19 41 23 38 55 66 92 111 126
Interest 1 0 1 1 1 0 2 1 1 1 1 1 1
Depreciation 8 7 13 19 23 32 37 47 45 53 66 73 78
Profit before tax 53 60 121 188 227 269 314 386 451 564 677 803 844
Tax % 23.0% 24.0% 21.0% 23.0% 22.0% 20.0% 20.0% 20.0% 16.0% 18.0% 20.0% 19.0% —
Net Profit + 41 46 96 145 177 215 251 308 377 461 541 650 678
EPS in Rs 5 6 13 19 23 28 32 40 50 60 71 84 88
Dividend Payout % 18.0% 20.0% 12.0% 10.0% 9.0% 9.0% 9.0% 10.0% 9.0% 8.0% 8.0% 9.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 78 113 210 349 582 858 954 1,252 1,649 2,084 2,619 3,355
Borrowings + 2 2 1 1 36 113 235 219 222 219 222 221
Other Liabilities + 134 137 133 136 109 139 159 250 305 380 352 446
Total Liabilities 229 267 358 500 743 1,126 1,364 1,736 2,191 2,698 3,208 4,038
Fixed Assets + 113 144 152 169 227 272 305 287 280 453 546 580
CWIP 31 0 3 15 10 20 14 18 221 117 144 234
Investments 0 0 17 47 70 61 11 89 281 376 590 859
Other Assets + 85 122 186 269 436 772 1,033 1,343 1,410 1,753 1,928 2,365
Total Assets 229 267 358 500 743 1,126 1,364 1,736 2,191 2,698 3,208 4,038
Equity Capital 15 15 15 15 15 15 15 15 15 15 15 15

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 50 42 68 66 83 45 269 337 271 318 432 523
Cash from Investing Activity + -23 -6 -36 -69 -100 -54 -30 -377 -216 -319 -333 -582
Cash from Financing Activity + -9 -14 -7 -12 90 80 -24 -41 -28 -38 -38 -46
Net Cash Flow 19 23 25 -14 73 70 215 -81 27 -39 61 -105
CFO/OP 103 92 73 53 54 38 102 106 81 77 86 87
Free Cash Flow 24 34 43 18 18 -32 195 246 78 173 241 275

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 70.62% → 70.57%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 26.08% 26.11% 24.95% 24.59% 23.93% 22.48% 21.72% 21.06% 20.82% 20.81% 21.14% 21.19%
Promoters 70.62% 70.62% 70.62% 70.56% 70.56% 70.56% 70.56% 70.56% 70.57% 70.57% 70.57% 70.57%
FII 3.09% 2.84% 3.33% 3.38% 3.71% 4.86% 5.73% 6.16% 6.51% 6.58% 6.15% 5.76%
DII 0.21% 0.43% 1.08% 1.49% 1.83% 2.11% 2.0% 2.22% 2.1% 2.05% 2.14% 2.49%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Caplin Point Lab Ltd. (this stock) 21,173 31.9 6.29 20.9%
Shilpa Medicare Ltd 19,821 69.7 7.67 8.99%
Granules India Limited 23,248 35.8 4.16 13.8%
Onesource Specl Pharma L 18,377 — 3.15 -1.09%
Pfizer Ltd 18,303 119.0 13.25 19.8%
Eris Lifesciences Limited 17,618 26.9 4.5 18.7%
Poly Medicure Limited 17,479 54.6 5.63 9.02%

Which Mutual Funds Hold Caplin Point Lab Ltd.?

Frequently Asked Questions about Caplin Point Lab Ltd.

Community Sentiment

What are other investors saying about Caplin Point Lab Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.